JP-SBPH@EC2704A

China Biopharma Plans 2 Billion HKD Stock Buyback Amid Price Volatility

Zhengda Tianqing Global R&D Headquarters Officially Opens in Shanghai Minhang with 1.8 Billion Investment

China Biopharma Announces Phase II Trial Culmerciclib Combination Hits Primary Endpoint

China Biopharma: Subsidiary's Innovative Drug Naldemedine Approved by NMPA for Launch

China Biopharm: Subsidiary's IDH1 Inhibitor TQB3454 Included in Priority Review

China Biopharma Subsidiary Hepzha Announces Phase I Clinical Data for Innovative Drug Kylo-0603

China Biopharmaceutical announces positive M701 trial results and drug application acceptance

China Biopharmaceutical's Jointly Promoted Drug Shenghetu Approved for First-Line NSCLC Treatment

China Biopharma's Zongertinib Approved by NMPA as First-Line Treatment for HER2-Mutated NSCLC

China Biopharma spends 10 million HKD to repurchase 1.89 million shares on May 18

China Biopharma spends 10.0269 million HKD to repurchase 1.87 million shares

China Biopharmaceutical Announces Preclinical Results of Obesity Treatment Candidate TQF6422

China Bio-Pharmaceuticals repurchased 1.78 million shares

China Biopharmaceutical bought back 1.81 million shares for HKD10.0149 million

China BioPharmaceuticals repurchasing 1.81 million shares

China Biologic Pharmaceutical's subsidiary Chengdu Tianqing Submits New Drug Application

China Biopharmaceutical repurchased 1.86 million shares at HKD5.38-5.44 per share and cancelled

China Biopharmaceutical's New Drug M701 Accepted by the National Medical Products Administration

China Biologic Products Recruits First Patient for LM-108 Phase III Clinical Trial

EDICO HOLDINGS

PARADISE ENT

FUTONG TECH

AUTO ITALIA

KNOWLEDGE ATLAS

ZIJING INTL FIN

SMC ELECTRIC

MICROWARE

ETHK LABS INC.

ZHONG JU INVEST

01177

Sino Biopharmaceutical (HK:1177) announced a HK$2 billion share purchase plan over the next 12 months to support its stock price, citing market undervaluation. The company has already repurchased shares worth HK$338 million this year and maintains sufficient financial resources. Management views this as a demonstration of confidence in its business outlook and aims to boost investor confidence. Analysts currently rate the stock as a Buy with a HK$6.50 target.

Tip Ranks

SBP GROUP

Sino Biopharmaceutical Unveils HK$2 Billion Share Purchase Plan to Support Stock and Shareholders

Sino Biopharmaceutical reported promising Phase II data for culmerciclib, an oral CDK2/4/6 inhibitor, in treating resistant breast cancer. The drug showed a 32.4% objective response rate and manageable safety profile when combined with fulvestrant. These results support its regulatory approval in China and potential to address resistance to existing therapies. With a fully enrolled Phase III trial underway, culmerciclib aims to strengthen Sino Biopharm's oncology portfolio. Analysts maintain a 'Buy' rating on the stock.

Sino Biopharm’s Culmerciclib Shows Promise in Resistant Breast Cancer

513120

159992

520690

520880

512010

SBIO

M Stanley updated its forecast for SBP GROUP, cutting the target price from HKD8.3 to HKD7.8 while maintaining an Overweight rating. The revision incorporates revenue expectations from the newly licensed bepirovirsen starting in 2027 and removes dividend assumptions from Sinovac LS from 2026. Consequently, EPS forecasts for 2026-2028 were lowered by 7-8%, and working capital and capex assumptions were adjusted to reflect recent trends.

AASTOCKS News

SINOVAC BIOTECH LTD

GF CSI HK Innovative Drugs Industry ETF(QDII)

Yinhua CSI Innovative Drugs Industry ETF

ChinaAMC CSI Biotechnology Theme ETF

iShares Biotechnology ETF

Tianhong CNI BIOMEDICINE ETF

China Universal 800 Health Care ETF

ChinaAMC SSE STAR Biology and Medicine ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Huaan Hang Seng Biotech ETF

First Trust NYSE Arca Biotech Index Fd

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

VanEck Biotech ETF

Direxion S&P Biotech Bear 3X

SPDR S&P Health

Penghua SSE STAR Biology and Medicine ETF

VG Health

ChinaAMC SSE Health Care ETF Initiating Fund

Proshares Ultra Nasdaq Biotech

Guotai SSE STAR Brand Name Drug ETF

SPDR S&P Biotech

Guotai CSI Bio-medicine ETF

E Fund CSI Biotechnology Theme ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

China Southern Hang Seng Biotech ETF(QDII)

China Merchants CSI Biotechnology Theme ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Minsheng Royal CSI Biotechnology Theme ETF

E Fund CSI 300 Health Care ETF

Dacheng CSI All Share Health Care Equipment and Services ETF

Health Care Select Sector SPDR

Penghua CSI HK Connect Health Care Composite ETF

Direxion S&P Biotech Bull 3X

Invesco Biotechnology & Genome ETF

Invesco Nasdaq Biotechnology ETF

ALPS Medical Breakthrough

iShares Global Healthcare

Ark Genomic Revolution ETF

Bosera Hang Seng Health Care ETF(QDII)

iShares US Pharma

Morgan Stanley

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

M Stanley Cuts SBP GROUP  TP to HKD7.8, Rating Overweight

GSK plc announced positive Phase III trial results for its hepatitis B treatment, bepirovirsen, with 19% of patients achieving a functional cure compared to 0% in the placebo group. In patients with lower viral activity, the cure rate rose to 26%. Additionally, 23% of treated patients maintained viral suppression at week 72 post-therapy. The trials involved over 1,800 participants and showed a safety profile similar to previous studies. Bepirovirsen is under priority review by the FDA, with regulatory decisions expected by Q3 2026.

nasdaq

GlaxoSmithKline plc

Nasdaq

GSK plc Sponsored ADR

GSK Says Bepirovirsen Achieves Phase III Functional Cure Goal In Chronic Hepatitis B

Sino Biopharmaceutical's subsidiary, Chia Tai Tianqing, presented promising preclinical data for TQF6422, a monoclonal antibody aimed at obesity treatment, at the European Congress on Obesity 2026. The drug demonstrated significant fat reduction and muscle preservation in animal models, outperforming competitors. With a favorable safety profile and plans for clinical trials, TQF6422 is part of a broader weight-loss pipeline, including other innovative therapies. Analysts rate Sino Biopharmaceutical (HK:1177) stock as a Buy, with a target price of HK$8.70, reflecting confidence in its growth in the obesity treatment market.

Sino Biopharm Showcases Promising Obesity Antibody Data and Expands Weight-Loss Pipeline

GSK has partnered with SBP Group to launch bepirovirsen in China, leveraging CTTQ's extensive network of over 5,000 medical centers. GSK will manage regulatory and quality oversight while SBP Group handles distribution and promotional activities. Bepirovirsen, an investigational treatment for chronic hepatitis B, aims to address a significant healthcare issue affecting 75 million people in China. The drug has received priority review and breakthrough designations in multiple countries. GSK's recent acquisition of SiranBio's therapy further supports its expansion into new treatment areas.

Pharmaceutical Business Review

Ionis Pharma

GSK and SBP Group team up to advance bepirovirsen launch in China

G Sachs has raised the target price for SBP GROUPto HKD8.05, maintaining a Buy rating following the company's agreement with GlaxoSmithKline (GSK) for exclusive commercialization rights in China for the hepatitis B drug bepirovirsen. The drug, expected to be approved in 2027, aligns with the treatment needs of China's 75 million chronic hepatitis B patients. G Sachs has increased its earnings forecasts for 2027 and 2028 by 1.1% and 1.7%, respectively, reflecting the anticipated sales contribution from bepirovirsen.

Founder Fubon CSI Medicine and Medical Device Innovation ETF

ICBCCS SSE STAR Biology and Medicine ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Goldman Sachs

GS Hldg R

G Sachs Raises SBP GROUP  TP to HKD8.05, Maintains Buy on Introduction of GSK Hepatitis B Drug

Sino Biopharmaceutical has announced that its subsidiary LaNova Medicines has enrolled the first patient in a Phase III clinical trial for cafelkibart (LM-108), a CCR8 monoclonal antibody, targeting advanced gastric cancer. This trial follows two Breakthrough Therapy Designations in China and aims to position LM-108 as a first-in-class therapy. Early data indicates improved response rates and survival compared to standard treatments. Analysts rate the stock as a Buy with a target price of HK$8.70, reflecting positive market sentiment.

Sino Biopharm Advances First-in-Class CCR8 Antibody Into Phase III Gastric Cancer Trial

JP-SBPH@EC2704A(29525.HK)